In the latest session, Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) closed at $5.72 down -2.05% from its previous closing price of $5.84. In other words, the price has decreased by -$0.12 from its previous closing price. On the day, 2036212 shares were traded.
Ratios:
For a deeper understanding of Aurinia Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.99 and its Current Ratio is at 5.50. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.22.
Oppenheimer Upgraded its Perform to Outperform on December 10, 2021, whereas the target price for the stock was revised from $33 to $31.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 27 when Knappertz Volker sold 4,930 shares for $6.10 per share. The transaction valued at 30,073 led to the insider holds 319,128 shares of the business.
Knappertz Volker sold 25,146 shares of AUPH for $137,800 on Feb 20. The EVP, Research and Development now owns 324,058 shares after completing the transaction at $5.48 per share. On Feb 20, another insider, Habig Scott Michael, who serves as the Chief Commercial Officer of the company, sold 15,867 shares for $5.48 each. As a result, the insider received 86,951 and left with 492,364 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AUPH now has a Market Capitalization of 844.57M and an Enterprise Value of 591.69M. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.71 while its Price-to-Book (P/B) ratio in mrq is 2.18. Its current Enterprise Value per Revenue stands at 3.37 whereas that against EBITDA is -9.38.
Stock Price History:
Over the past 52 weeks, AUPH has reached a high of $12.43, while it has fallen to a 52-week low of $5.35. The 50-Day Moving Average of the stock is 7.91, while the 200-Day Moving Average is calculated to be 8.88.
Shares Statistics:
For the past three months, AUPH has traded an average of 2.53M shares per day and 5.23M over the past ten days. A total of 143.83M shares are outstanding, with a floating share count of 127.57M. Insiders hold about 11.79% of the company’s shares, while institutions hold 36.54% stake in the company. Shares short for AUPH as of Feb 15, 2024 were 16.85M with a Short Ratio of 6.65, compared to 16.39M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 11.65% and a Short% of Float of 11.69%.
Earnings Estimates
There are 6 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.13 for the current quarter, with a high estimate of $0.01 and a low estimate of -$0.2, while EPS last year was -$0.18. The consensus estimate for the next quarter is -$0.02, with high estimates of $0.04 and low estimates of -$0.06.
Analysts are recommending an EPS of between $0.15 and -$0.34 for the fiscal current year, implying an average EPS of -$0.05. EPS for the following year is $0.4, with 6 analysts recommending between $0.87 and -$0.14.
Revenue Estimates
A total of 6 analysts believe the company’s revenue will be $47.45M this quarter.It ranges from a high estimate of $51.82M to a low estimate of $46M. As of the current estimate, Aurinia Pharmaceuticals Inc’s year-ago sales were $34.41M, an estimated increase of 37.90% from the year-ago figure.
A total of 6 analysts have provided revenue estimates for AUPH’s current fiscal year. The highest revenue estimate was $232.83M, while the lowest revenue estimate was $207M, resulting in an average revenue estimate of $224.25M. In the same quarter a year ago, actual revenue was $175.51M, up 27.80% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $288.87M in the next fiscal year. The high estimate is $339.89M and the low estimate is $250M. The average revenue growth estimate for next year is up 28.80% from the average revenue estimate for this year.
